Alcon announced last week that it is acquiring Aerie Pharmaceuticals. Through the deal, Alcon will add Rocklatan and Rhopressa to its portfolio.
The deal also includes phase 3 product candidate, AR-15512, which is being evaluated as a treatment for the signs and symptoms of dry eye disease.
In addition, Aerie holds a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates, including three retinal implants (AR-115, AR-13503 SR, and AR-14034 SR) for the treatment of AMD and DME.
Didn't Alcon just buy something else?
A few things, actually. In April 2021, Alcon bought Simbrinza from Novartis, and this past May, the company bought Eysuvis and Inveltys from Kala Pharmaceuticals.
Alcon also finalized its acquisition of Ivantis, developer of the Hydrus Microstent, earlier this year. The transaction is the latest in a series of moves by Alcon to expand its presence in the ophthalmic pharmaceutical eye drop space.